Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: A phase I-II study

C. Tibaldi, T. Prochilo, F. Russo, M. C. Pennucci, A. Del Freo, F. Innocenti, A. Fabbri, A. Falcone, P. F. Conte, E. Baldini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses were epirubicin (EpiDX) 90 mg m-2 and paclitaxel (P) 175 mg m -2 with febrile neutropenia as dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75 mg m-2, P 175 mg m-2, etoposide (E) 100 mg m-2 intravenous (fixed dose) days 1-3 with courses repeated every 21 days. The prophylactic use of colony-stimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50-70), median Eastern Cooperative Oncology Group performance status 0 (0-2); nine patients had visceral disease and 17 had more than two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1-6) per patients. Main toxicity (NCI-CTC) was myelosuppression: neutropenia grades 3 and 4 in 16 and 35% of the courses, respectively. Seven episodes of febrile neutropenia were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19 evaluable patients achieved a complete response (37%), nine patients (47.3%) a partial response with an overall response rate of 84.2% ((95% confidence interval = 60.4-96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/ etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the haematological profile.

Original languageEnglish
Pages (from-to)1263-1266
Number of pages4
JournalBritish Journal of Cancer
Volume94
Issue number9
DOIs
Publication statusPublished - May 8 2006

Fingerprint

Epirubicin
Small Cell Lung Carcinoma
Etoposide
Paclitaxel
Colony-Stimulating Factors
Febrile Neutropenia
Maximum Tolerated Dose
Neutropenia
Appointments and Schedules
Confidence Intervals

Keywords

  • Epirubicin
  • Etoposide
  • Paclitaxel
  • SCLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tibaldi, C., Prochilo, T., Russo, F., Pennucci, M. C., Del Freo, A., Innocenti, F., ... Baldini, E. (2006). Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: A phase I-II study. British Journal of Cancer, 94(9), 1263-1266. https://doi.org/10.1038/sj.bjc.6603074

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer : A phase I-II study. / Tibaldi, C.; Prochilo, T.; Russo, F.; Pennucci, M. C.; Del Freo, A.; Innocenti, F.; Fabbri, A.; Falcone, A.; Conte, P. F.; Baldini, E.

In: British Journal of Cancer, Vol. 94, No. 9, 08.05.2006, p. 1263-1266.

Research output: Contribution to journalArticle

Tibaldi, C, Prochilo, T, Russo, F, Pennucci, MC, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, PF & Baldini, E 2006, 'Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: A phase I-II study', British Journal of Cancer, vol. 94, no. 9, pp. 1263-1266. https://doi.org/10.1038/sj.bjc.6603074
Tibaldi C, Prochilo T, Russo F, Pennucci MC, Del Freo A, Innocenti F et al. Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: A phase I-II study. British Journal of Cancer. 2006 May 8;94(9):1263-1266. https://doi.org/10.1038/sj.bjc.6603074
Tibaldi, C. ; Prochilo, T. ; Russo, F. ; Pennucci, M. C. ; Del Freo, A. ; Innocenti, F. ; Fabbri, A. ; Falcone, A. ; Conte, P. F. ; Baldini, E. / Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer : A phase I-II study. In: British Journal of Cancer. 2006 ; Vol. 94, No. 9. pp. 1263-1266.
@article{503f0a5619d24b058ccf1a436fe51374,
title = "Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: A phase I-II study",
abstract = "The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses were epirubicin (EpiDX) 90 mg m-2 and paclitaxel (P) 175 mg m -2 with febrile neutropenia as dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75 mg m-2, P 175 mg m-2, etoposide (E) 100 mg m-2 intravenous (fixed dose) days 1-3 with courses repeated every 21 days. The prophylactic use of colony-stimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50-70), median Eastern Cooperative Oncology Group performance status 0 (0-2); nine patients had visceral disease and 17 had more than two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1-6) per patients. Main toxicity (NCI-CTC) was myelosuppression: neutropenia grades 3 and 4 in 16 and 35{\%} of the courses, respectively. Seven episodes of febrile neutropenia were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19 evaluable patients achieved a complete response (37{\%}), nine patients (47.3{\%}) a partial response with an overall response rate of 84.2{\%} ((95{\%} confidence interval = 60.4-96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/ etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the haematological profile.",
keywords = "Epirubicin, Etoposide, Paclitaxel, SCLC",
author = "C. Tibaldi and T. Prochilo and F. Russo and Pennucci, {M. C.} and {Del Freo}, A. and F. Innocenti and A. Fabbri and A. Falcone and Conte, {P. F.} and E. Baldini",
year = "2006",
month = "5",
day = "8",
doi = "10.1038/sj.bjc.6603074",
language = "English",
volume = "94",
pages = "1263--1266",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer

T2 - A phase I-II study

AU - Tibaldi, C.

AU - Prochilo, T.

AU - Russo, F.

AU - Pennucci, M. C.

AU - Del Freo, A.

AU - Innocenti, F.

AU - Fabbri, A.

AU - Falcone, A.

AU - Conte, P. F.

AU - Baldini, E.

PY - 2006/5/8

Y1 - 2006/5/8

N2 - The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses were epirubicin (EpiDX) 90 mg m-2 and paclitaxel (P) 175 mg m -2 with febrile neutropenia as dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75 mg m-2, P 175 mg m-2, etoposide (E) 100 mg m-2 intravenous (fixed dose) days 1-3 with courses repeated every 21 days. The prophylactic use of colony-stimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50-70), median Eastern Cooperative Oncology Group performance status 0 (0-2); nine patients had visceral disease and 17 had more than two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1-6) per patients. Main toxicity (NCI-CTC) was myelosuppression: neutropenia grades 3 and 4 in 16 and 35% of the courses, respectively. Seven episodes of febrile neutropenia were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19 evaluable patients achieved a complete response (37%), nine patients (47.3%) a partial response with an overall response rate of 84.2% ((95% confidence interval = 60.4-96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/ etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the haematological profile.

AB - The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses were epirubicin (EpiDX) 90 mg m-2 and paclitaxel (P) 175 mg m -2 with febrile neutropenia as dose-limiting toxicity. The recommended schedule for this regimen for the phase II study was EpiDX 75 mg m-2, P 175 mg m-2, etoposide (E) 100 mg m-2 intravenous (fixed dose) days 1-3 with courses repeated every 21 days. The prophylactic use of colony-stimulating factors (CSFs) was not allowed. Twenty patients entered the phase II trial: median age was 61 years (range 50-70), median Eastern Cooperative Oncology Group performance status 0 (0-2); nine patients had visceral disease and 17 had more than two metastatic sites. A total of 100 courses were administered with a median of 5 (range 1-6) per patients. Main toxicity (NCI-CTC) was myelosuppression: neutropenia grades 3 and 4 in 16 and 35% of the courses, respectively. Seven episodes of febrile neutropenia were documented and one patient required hospital admission. Nonhaematological toxicity was moderate. Seven out of 19 evaluable patients achieved a complete response (37%), nine patients (47.3%) a partial response with an overall response rate of 84.2% ((95% confidence interval = 60.4-96.6)). In this poor prognostic population of patients the triplet epirubicin/paclitaxel/ etoposide showed high antitumour activity with mild nonhaematological side effects. The use of CSFs should be able to improve the haematological profile.

KW - Epirubicin

KW - Etoposide

KW - Paclitaxel

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=33646509237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646509237&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603074

DO - 10.1038/sj.bjc.6603074

M3 - Article

C2 - 16622468

AN - SCOPUS:33646509237

VL - 94

SP - 1263

EP - 1266

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -